OTCMKTS:EKTAY - Elekta AB (publ) Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$13.61
▼ -0.13 (-0.95%)
1 month | 3 months | 12 months
Get New Elekta AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EKTAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EKTAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Elekta AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.61.
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Elekta AB (publ). This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 2 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/18/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
1/20/2021Berenberg BankReiterated RatingBuy
i
1/7/2021Northland SecuritiesInitiated CoverageOutperform
i
12/9/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight
i
11/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
Rating by David Adlington at JPMorgan Chase & Co.
10/26/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
Rating by David Adlington at JPMorgan Chase & Co.
9/9/2020Morgan StanleyReiterated RatingEqual Weight
i
9/3/2020Berenberg BankReiterated RatingBuy
i
8/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
Rating by David Adlington at JPMorgan Chase & Co.
8/3/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
7/29/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
i
6/1/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
i
5/7/2020UBS GroupDowngradeBuy ➝ Neutral
i
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
i
2/21/2020Pareto SecuritiesDowngradeBuy ➝ Hold
i
7/16/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold
i
11/28/2018UBS GroupUpgradeNeutral ➝ Buy
i
11/13/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
12/7/2016Jefferies Financial GroupDowngradeHold ➝ Underperform
i
(Data available from 4/21/2016 forward)
Elekta AB (publ) logo
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Read More

Today's Range

Now: $13.61
$13.50
$13.62

50 Day Range

MA: $13.35
$12.73
$13.97

52 Week Range

Now: $13.61
$8.46
$15.19

Volume

1,558 shs

Average Volume

2,959 shs

Market Capitalization

$5.20 billion

P/E Ratio

39.37

Dividend Yield

1.02%

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Elekta AB (publ)?

The following equities research analysts have issued stock ratings on Elekta AB (publ) in the last twelve months: Berenberg Bank, JPMorgan Chase & Co., Morgan Stanley, Northland Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for EKTAY.

What is the current price target for Elekta AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Elekta AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Elekta AB (publ) in the next year.
View the latest price targets for EKTAY.

What is the current consensus analyst rating for Elekta AB (publ)?

Elekta AB (publ) currently has 2 sell ratings, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EKTAY, but not buy more shares or sell existing shares.
View the latest ratings for EKTAY.

What other companies compete with Elekta AB (publ)?

How do I contact Elekta AB (publ)'s investor relations team?

Elekta AB (publ)'s physical mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company's listed phone number is 46-8-587-254-00 and its investor relations email address is [email protected] The official website for Elekta AB (publ) is www.elekta.com.